an apoptotic response and was found to be dependent upon Cyclin E expression. Finally, we found that combinations with cisplatin or PARP inhibitors enhanced the anti-tumour cell effect of ATRi, suggesting that either single agent ATRi or combination therapy involving ATRi might be further assessed as candidate approaches for SS treatment.
Introduction
Synovial sarcoma (SS) is a rare, yet aggressive and difficult to treat type of soft tissue sarcoma (STS) that has a variable age of onset but predominantly affects young adults. Although for patients with localized disease, wide surgical excision combined with radiotherapy can be curative, recurrent disease is common (1) . In the metastatic setting, SS patients are treated with cytotoxic chemotherapies, including the topoisomerase inhibitor doxorubicin and/or the alkylating agent ifosfamide. Recently, the multi-kinase inhibitor pazopanib became the first targeted agent to be approved for the treatment of advanced SS after failure of anthracycline containing chemotherapy (2).
Despite these multimodal therapy approaches, the outcome of metastatic SS patients remains poor; those with distant metastasis have a 10-year survival rate of only 8.9% compared to 69% for patients with localized tumours (3).
These factors highlight that additional, more specific therapeutic approaches with greater efficacy are required to effectively manage this disease.
The main pathological driver event in SS is known, suggesting that in principle at least, mechanism-based targeted approaches to treating SS could be developed. The majority of SS are characterised by a t(X;18) reciprocal chromosomal translocation, often used as a diagnostic biomarker for the disease (4). These t(X;18) translocations fuse the first 10 exons of the SS18 (synovial sarcoma translocation, chromosome 18) gene to the last three exons of one of the SSX (synovial sarcoma, X breakpoint) family of genes, SSX1, SSX2 or SSX4 (4, 5) , encoding either SS18-SSX1, SS18-SSX2, or SS18-SSX4 fusion proteins. SS display few other recurrent mutations (6) .
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A number of studies have aimed to identify the cellular functions of these oncogenic fusions as well as of their wild-type SS18 and SSX counterparts (7, 8) . SS18-SSX oncoproteins contribute to the dysregulation of gene expression through association with SWI/SNF (BAF) and Polycomb chromatin remodelling complexes (9) (10) (11) . BAF complexes mediate nucleosome remodelling via an ATP-dependent process and in doing so modulate transcription (12, 13) , DNA repair and the maintenance of genomic integrity (13, 14) . SS18-SSX1 fusion proteins displace wild-type SS18 and an additional BAF component, the tumour suppressor SMARCB1, from BAF complexes (7) . The displacement of SMARCB1 from BAF leads to its proteasomal degradation, with reduced levels of BAF-associated SMARCB1 being a characteristic of SS tumour cell lines and tumours (7, 15) .
Despite an enhanced understanding SS18-SSX function, therapeutic targeting of these oncogenic proteins has not yet been achieved. One of the more recently used approaches to identifying therapeutic targets in cancer has been to identify and exploit genetic dependencies, such as synthetic lethal and gene addiction effects, that are associated with particular cancer driver gene defects. The potential of such an approach is best exemplified by the use of small molecule PARP inhibitors in BRCA1/2 mutant cancers (16, 17) .
Since the key driver genotype of SS is well-established, we sought to apply a similar approach to identify synthetic lethal interactions in SS. This identified an unexpected dependency in SS tumour cells upon on the kinase ATR (Ataxia Telangiectasia mutated and Rad3-related), a key mediator of the DNA ATR is a therapeutic target in synovial sarcoma 6 damage response (DDR) (18) that can be exploited with clinical ATR inhibitors.
Materials and Methods
Cell culture
Yamato-SS and Aska-SS cell lines were kindly provided by Kazuyuki Itoh and Norifumi Naka (Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan); Akira Kawai (National Cancer Center Hospital, Tokyo, Japan) provided SYO-1 cells and Cinzia Lanzi (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy) provided CME-1 cells. HS-SY-II cells were obtained from the RIKEN BioResource Center. HCT116 WT and ARID1A-mutant isogenic cell lines have been described previously (19) ; all other cell lines were supplied by ATCC. Cells were grown in 5% CO 2 at 37°C in media described below, supplemented with 15% (HFFI) or 10% (all other cell lines) fetal calf serum (FCS, Gibco) and 1% Pen-Strep (Sigma). Media for cell lines was as follows: Yamato-SS = Dulbecco's Modified Eagle Medium (DMEM; Gibco); Aska-SS= DMEM; SYO-1= DMEM; CME-1 = RPMI 1640 Medium (Gibco); HS-SY-II = DMEM; HCT116 = McCoy's 5A Medium (Gibco); U2OS = DMEM; HFF1 = DMEM. All cell lines were obtained between 2010 and 2016 and their identities were confirmed by in-house STR typing and, where appropriate, by PCR/Sanger sequencing confirmation of SS-specific gene fusions. Mycoplasma testing was carried out on each cell line every five passages (all negative). Cells were grown for no longer than 25 passages in total for any experiment.
siRNA screens
Cells lines were reversed transfected with a Dharmacon SMARTpool 384 well plate-arrayed siRNA library designed to target 714 kinases and kinase-related genes, 320 Wnt-pathway associated genes, 80 tumour suppressor genes, and 480 genes recurrently altered in human cancers (Supplementary Table 1) as described in (20). Positive control (siPLK1) and multiple negative controls . Screens were performed in triplicate. Cell viability was estimated five days after transfection using CellTiter-Glo assay (Promega). Data processing and quality controls were performed using the cellHTS2 R package as described previously (20, 21) . In the case of the VX970 resistance screen (Figure 4 ), 24h after transfection, VX970 (final concentration 0.75 μM) or vehicle (DMSO) was added to cells. Cells were then exposed to VX970 for four days and viability estimated with CellTiter-Glo assay as above. Drug effect (DE) Z-scores were calculated as described previously (22) .
Chemosensitisation screens, dose/response cell survival assays, assessment of apoptosis
Screens were carried out and analysed as in (22) . In brief, SYO-1 and HS-SY-II cells were exposed to 0.04 μM VX970 plus a drug library of 79 small molecules (Supplementary Table 2 ), in a 384-well-plate format. After five days ATR is a therapeutic target in synovial sarcoma 8 drug exposure, cell viability was estimated with CellTiter-Glo assay (Promega). Screens were carried out in triplicate. For dose/response cell survival assays, cells were plated in 384 well plates at 250-500 cells per well, and appropriate drug concentrations were added 24 hours later. Cell viability was estimated five days later using CellTiter-Glo. For drug combination assays, synergy was determined using MacSynergy II (23) . Cell apoptosis was assessed using the Promega Caspase-Glo 3/7 assay as per the manufacturer's instructions.
Western blotting
Cells were harvested and lysed using NET-N lysis buffer supplemented with protease and phosphatase inhibitors (Roche) and sonicated for five seconds. 
Lentiviral SS18-SSX expression
SS18-SSX1, SS18-SSX2 and the SS18-SSX1 71-78 mutant cDNAs were ATR is a therapeutic target in synovial sarcoma 9 cloned into the pLX301 lentiviral transfer vector (7) . For viral infection, cells were plated in 6-well plates and exposed to 0.5 ml lentiviral filtrate. After three days, cells were transferred to a T25 flask containing 1 μg/ml puromycin (Gibco) to remove non-transduced cells. After three days selection in puromycin, cells were harvested and used for further analysis. GFP expression was confirmed in GIPZ-infected cells using an EVOS FL fluorescence microscope (Life Technologies).
FACS analysis
Cells were cultured in 6-well plates and exposed to either 0.5 μM VX970 or 
DNA fibre analysis
DNA fibre assays were carried out as described previously (24) .
In vivo studies
In vivo efficacy studies were performed using SA13412 patient-derived SS 
Results
RNA interference profiling of SS cell lines identifies ATR as a candidate genetic dependency
To identify candidate therapeutic targets in SS, we carried out large-scale small interfering RNA (siRNA) screens in five commonly-used SS tumour cell lines; HS-SY-II, Aska-SS, Yamato-SS, CME-1 and SYO-1 ( Figure 1A ). These cell lines were selected as they harbour either one of the two most common SS-associated fusions (SS18-SSX1 or SS18-SSX2), and were amenable to high-efficiency siRNA transfection in a 384-well plate format ( Figure 1B -D).
After optimising high-throughput transfection conditions, each cell line was reverse-transfected with a 384-well plate-arrayed siRNA library designed to target 1600 genes (Supplementary Table 1 and Methods), including pharmacologically tractable kinase-coding and kinase-related genes, Wntpathway-associated genes given their role in SS (11, 25, 26) and genes recurrently altered in human cancers (27) . Cell viability was measured after five days and this data then used to identify those siRNAs that caused significant tumour cell growth inhibition (i.e. genetic dependencies). Robust Zscores were calculated from three replica screens (Methods and Supplementary Figure 2E ) and extended the survival of tumourbearing mice (log-rank test p=0.0451, Figure 2F ). Furthermore, we found that SS tumour cells generated nuclear RAD51 foci in response to ATRi, hydroxyurea or IR (Supplementary Figure 3D) , suggesting that a defect in RAD51-mediated DNA repair processes might not explain ATRi sensitivity. ATRi sensitivity has also been associated with a reduction in chromatin bound topoisomerase levels (32). Again, we did not observe a clear defect in chromatin-TOP2A levels that could explain the profound ATRi sensitivity (Supplementary Figure 3E -J).
SS18-SSX1 or SS18-SSX2 fusion proteins induce
ATRi causes apoptosis and replication fork stress in SS tumour cells
In addition to ATR, our siRNA screens suggested that SS tumour cells were also reliant upon additional proteins involved in the replication fork stress response, including RAD9A and RAD18 ( Figure 1N-O) . As well as finding that SS tumour cells exposed to ATRi exhibited biomarkers of an apoptotic response (caspase 3/7 and PARP1 cleavage ( Figure 3A-B) ), we noted that ATRi induced pan-nuclear phosphorylation of histone H2AX ( H2AX), which is a biomarker of replication fork stress ( Figure 3B-E) . To assess the replication fork stress phenotype in more detail, we used DNA fibre analysis (24) and found that VX970 exposure caused a significant reduction in replication fork speed in SYO-1 SS tumour cells (p<0.0001, paired t-test, Figure 3F , Supplementary Figure 4A-B) . In addition, ectopic expression of SS18-SSX1 fusion protein in HCT116 cells caused a modest but significant decrease in replication fork speed (p<0.0001, paired t-test), an effect enhanced by exposure to VX970 ( Figure 3G, Supplementary Figure 4C ). This suggested that the SS18-SSX1 fusion protein might cause an increase in replication fork stress, which is in turn enhanced by ATR inhibition. One cause of replication fork stress is steric interference between DNA replication and transcriptional machineries, often associated with R-loops, DNA-RNA hybrid structures that activate ATR-mediated DNA damage responses (38) . We reasoned that an enhanced transcriptional programme caused by SS fusion expression might cause R-loops. R-loop frequency can be estimated by the immunohistochemical detection of DNA-RNA hybrid structures (38) . We found that the exposure of SYO-1 cells to VX970 enhanced the R-loop IHC signal (p<0.001, Student's t-test, Figure 3H ). The expression of the SS18-SSX1 fusion in HCT116 cells also caused a modest but significant increase in Rloop IHC signal (p<0.001, Student's t-test), which was enhanced by the addition of VX970 (p<0.001, Student's t-test, Figure 3I ).
As previous studies have demonstrated that ATRi prevents normal replication of DNA under oncogene-induced replication fork stress (39), we performed FACS cell-cycle analysis to determine whether a similar effect operated in SS cells. SYO-1 cells were pulse-labelled with EdU, which is incorporated into DNA during active DNA synthesis. Cells exposed to VX970 exhibited a profound reduction in the fraction of cells in active S-phase (from 30% to 8% after 48 hours VX970 exposure ( Figure 3J, Supplementary Figure 4D) ),
suggesting that ATRi exposure in SS tumour cells impaired DNA replication, consistent with our previous observations.
ATRi sensitivity in SS tumour cells is Cyclin E dependent
To gain more insight into the processes involved in ATRi sensitivity, we took a relatively unbiased approach using an siRNA "resistance" screen to identify genes that could reverse the ATRi sensitivity phenotype in a SS tumour cell line. SYO-1 cells were reverse-transfected in a 384-well plate format with the siRNA library described earlier, and 24h later exposed to either a relatively We also assessed known synergistic combinations with ATRi, as well as assessing the effects of combining ATRi with standard-of-care agents used in SS. For example, in non-SS tumour cells, the combination of VX970 with platinum salts has been reported as synergistic (33); we found that the combination of VX970 and cisplatin generated a synergistic effect on cell inhibition in both SYO-1 and HS-SY-II cells, generating synergy volumes of 465 μM 2 and 334 μM 2 , respectively ( Figure 5E-H) . This combinatorial effect also elicited a survival benefit in mice bearing HS-SY-II SS tumour xenografts (p=0.0424, log-rank test, Figure 5I ). Finally, we also assessed combinations of VX970 when used with cytotoxic agents used in the treatment of SS (doxorubicin and the alkylating chemotherapeutic cyclophosphamide) as well as the targeted drug used in SS treatment pazopanib (2). We observed largely non-synergistic effects in each of these cases, although in HS-SY-II cells, the combination of VX970 plus the active derivate of cyclophosphamide (4-HC) caused a mild synergistic effect (Supplementary Figure 5) .
Discussion
In this study, high-throughput siRNA screening of SS cell lines identified a selective and novel dependency upon the DDR-related kinase ATR.
Validation studies confirmed a synthetic lethal interaction between SS18-SSX fusion genes and ATR and established that ATRi might be used to exploit this effect.
The sensitivity of SS to DDR-targeting drugs was rather unexpected. To date, as compared to controls. p-value calculated by log-rank test.
